Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5821MR)

This product GTTS-WQ5821MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5821MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7962MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ5494MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ8568MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ5372MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3259MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ12816MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ7986MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ14047MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW